Published in Blood Weekly, December 13th, 2007
Conventional, mature products continue to generate the majority of sales. However, their growth rate is slow and limited by the maturity of the product and the competition. Advancements in biotechnology, biomaterials, and tissue engineering are expected to drive growth during the forecast period. According to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.